News
CRBU
1.300
-0.76%
-0.010
Weekly Report: what happened at CRBU last week (0907-0911)?
Weekly Report · 6d ago
Weekly Report: what happened at CRBU last week (0831-0904)?
Weekly Report · 09/07 09:52
Weekly Report: what happened at CRBU last week (0824-0828)?
Weekly Report · 08/31 09:57
Here's Why You Should Retain IQVIA Stock in Your Portfolio Now
NASDAQ · 08/26 15:17
Weekly Report: what happened at CRBU last week (0817-0821)?
Weekly Report · 08/24 09:58
RBC Capital Keeps Their Buy Rating on Caribou Biosciences (CRBU)
TipRanks · 08/17 10:29
Weekly Report: what happened at CRBU last week (0810-0814)?
Weekly Report · 08/17 09:58
Caribou Biosciences reports Q2 EPS (24c), consensus (31c)
TipRanks · 08/16 14:03
Caribou Biosciences price target lowered to $5 from $6 at BofA
TipRanks · 08/16 13:45
Caribou Biosciences Price Target Cut to $5.00/Share From $6.00 by B of A Securities
Dow Jones · 08/14 18:35
Caribou Biosciences Is Maintained at Buy by B of A Securities
Dow Jones · 08/14 18:35
B of A Securities Maintains Buy on Caribou Biosciences, Lowers Price Target to $5
Benzinga · 08/14 18:25
Adicet Bio: A Cheap Gamma Delta T-Cell Play
Seeking Alpha · 08/14 17:18
Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Caribou Biosciences (CRBU) and Aveanna Healthcare Holdings (AVAH)
TipRanks · 08/14 11:20
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Caribou Biosciences (CRBU), Bristol-Myers Squibb (BMY) and Schrodinger (SDGR)
TipRanks · 08/14 09:40
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Lags Revenue Estimates
NASDAQ · 08/13 22:05
Press Release: Caribou Biosciences Reports Second -2-
Dow Jones · 08/13 20:05
Weekly Report: what happened at CRBU last week (0803-0807)?
Weekly Report · 08/10 09:55
Spotlight On Promising Penny Stocks For August 2026
Simply Wall St · 08/06 17:05
Weekly Report: what happened at CRBU last week (0727-0731)?
Weekly Report · 08/03 09:54
More
Webull provides a variety of real-time CRBU stock news. You can receive the latest news about Caribou Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CRBU
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. The Company is dedicated to developing transformative therapies for patients with devastating diseases. The Company's chRDNA genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is focused on vispacabtagene regedleucel (vispa-cel) and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies. Vispa-cel is an allogeneic anti-CD19 CAR-T cell therapy that has been evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma. CB-011 is an allogeneic anti-BCMA CAR-T cell therapy that is being evaluated in patients with relapsed or refractory multiple myeloma.